Anatomy & Physiology II · In-depth topic guides

Hemostasis and Blood Typing

On this page 6 sections

In 30 seconds
The college version
Eli explains
Check yourself
Quick check
Study tools

In 30 seconds

This topic covers the body's mechanisms for stopping bleeding (hemostasis) — from immediate vascular spasm through platelet plug formation and the coagulation cascade to clot removal via fibrinolysis — and the genetic basis of blood groups (ABO and Rh) that govern transfusion compatibility. Understanding these processes is essential for clinical practice: mismatched transfusions can trigger fatal hemolytic reactions, and defects in hemostatic pathways underlie disorders like hemophilia and dangerous clot formation (thrombosis).

The college version

Detailed Notes

2.1 Hemostasis Overview

Hemostasis is the physiological process that prevents blood loss from damaged vessels. It operates through three rapid, overlapping phases:

Vascular spasm — immediate vasoconstriction to reduce blood flow
Platelet plug formation — platelets adhere, activate, and aggregate at the injury site
Coagulation (clotting) — a cascade of enzymatic reactions that converts soluble fibrinogen into insoluble fibrin threads, reinforcing the platelet plug

After the vessel heals, fibrinolysis dissolves the clot to restore normal blood flow. These processes are tightly balanced by natural anticoagulants; disruption in either direction leads to bleeding disorders or unwanted clotting.

2.2 Phase 1: Vascular Spasm (Vasoconstriction)

When a blood vessel is injured, the smooth muscle in its wall contracts immediately. This vascular spasm narrows the vessel lumen, reducing blood loss within seconds.

Triggered by: direct mechanical stimulation of smooth muscle, chemicals released by damaged endothelial cells (e.g., endothelin), and reflex neural signals from pain receptors
Duration: typically lasts 20–30 minutes
Clinical relevance: more effective in smaller vessels; large arterial injuries overwhelm this mechanism

2.3 Phase 2: Platelet Plug Formation

Platelets are small, anucleate cell fragments circulating in blood. When a vessel is injured, they undergo three key steps:

Step 1: Platelet Adhesion

Exposed collagen fibers in the damaged vessel wall bind von Willebrand factor (vWF), a large plasma protein. Platelets express glycoprotein Ib (GPIb) receptors that grab onto vWF, tethering them to the injury site.

Step 2: Platelet Activation

Adherent platelets change shape from smooth discs to spiky spheres with extended pseudopods. They release the contents of their granules:

ADP and thromboxane A₂ — recruit and activate more platelets
Serotonin — enhances local vasoconstriction
These chemicals make nearby platelets "sticky" by exposing GPIIb/IIIa receptors on their surface

Step 3: Platelet Aggregation

Fibrinogen bridges form between GPIIb/IIIa receptors on adjacent platelets, linking them together into a platelet plug. This plug is temporary (the white thrombus) and must be reinforced by fibrin to withstand the force of flowing blood.

Key player: von Willebrand factor (vWF) is essential for platelet adhesion under high-shear conditions (arteries, arterioles). Deficiency causes von Willebrand disease, the most common inherited bleeding disorder.

2.4 Phase 3: The Coagulation Cascade

The coagulation cascade transforms liquid blood into a gel-like clot by generating fibrin. It involves a series of clotting factors (mostly serine proteases produced by the liver) that circulate as inactive zymogens and activate each other in sequence. The cascade has two entry points that converge onto a common pathway.

Intrinsic Pathway (Contact Activation Pathway)

Triggered when factor XII (Hageman factor) contacts negatively charged surfaces such as exposed collagen or glass (in vitro). All components are already present in the blood.

Sequence: XII → XIIa → XI → XIa → IX → IXa (with factor VIIIa as cofactor) → activates factor X

Extrinsic Pathway (Tissue Factor Pathway)

Triggered by tissue damage that exposes tissue factor (TF, also called factor III) from subendothelial cells. This is the in vivo primary pathway and is much faster.

Sequence: Tissue factor + factor VII → VIIa–TF complex → directly activates factor X

Common Pathway

Both pathways converge at factor X activation:

Factor Xa combines with factor Va (cofactor) on platelet surfaces to form the prothrombinase complex
Prothrombinase cleaves prothrombin (factor II) → thrombin (factor IIa)
Thrombin cleaves soluble fibrinogen (factor I) → insoluble fibrin monomers
Fibrin monomers polymerize into long strands, forming a mesh
Factor XIIIa (activated by thrombin) cross-links fibrin strands with covalent bonds, stabilizing the clot

Thrombin is the central enzyme of coagulation. It not only converts fibrinogen to fibrin but also activates factors V, VIII, XI, and XIII — creating powerful positive feedback loops.

Comparison of Coagulation Pathways

Feature	Intrinsic Pathway	Extrinsic Pathway	Common Pathway
Trigger	Contact with collagen / negatively charged surface	Tissue factor exposure from damaged cells	Factor X activation
Location of factors	All in plasma	Requires tissue factor (extravascular)	On platelet surfaces
Speed	Slower (minutes)	Fast (seconds)	N/A
Key initiator	Factor XII (Hageman factor)	Factor VII + Tissue Factor (III)	Factor Xa
Clinical test	aPTT (activated partial thromboplastin time)	PT (prothrombin time) / INR	Both aPTT and PT prolonged
Primary role	Amplification	In vivo initiation of clotting	Final fibrin generation

Key Coagulation Factors

Factor Number	Name	Pathway	Notes
I	Fibrinogen	Common	Converted to fibrin by thrombin
II	Prothrombin	Common	Converted to thrombin by Xa/Va
III	Tissue Factor / Thromboplastin	Extrinsic	Released from damaged tissue
IV	Calcium ions (Ca²⁺)	All	Required cofactor for many steps
VII	Proconvertin	Extrinsic	Vitamin K-dependent
VIII	Antihemophilic factor A	Intrinsic	Deficiency → Hemophilia A
IX	Christmas factor	Intrinsic	Deficiency → Hemophilia B; Vitamin K-dependent
X	Stuart-Prower factor	Common	Convergence point; Vitamin K-dependent
XI	Plasma thromboplastin antecedent	Intrinsic	Activated by XIIa
XII	Hageman factor	Intrinsic	Contact activation
XIII	Fibrin-stabilizing factor	Common	Cross-links fibrin

Vitamin K-dependent factors: II, VII, IX, and X. These require vitamin K for hepatic synthesis of functional proteins. The anticoagulant warfarin acts by inhibiting vitamin K recycling.

2.5 Clot Retraction and Fibrinolysis

Clot Retraction

After the fibrin mesh forms, platelets contract their actin-myosin cytoskeleton, pulling on fibrin threads and squeezing out serum (plasma without clotting factors). This clot retraction draws the vessel edges closer together and promotes healing. It occurs within 30–60 minutes of clot formation.

Fibrinolysis

Once the vessel wall is repaired, the clot must be removed. Fibrinolysis is the enzymatic breakdown of fibrin:

Endothelial cells release tissue plasminogen activator (tPA) in response to clot presence
tPA converts the inactive plasma protein plasminogen → active plasmin
Plasmin digests fibrin strands into soluble fibrin degradation products (FDPs)
The clot dissolves and blood flow is restored

Clinical use: Recombinant tPA (alteplase) is given to dissolve pathological clots in ischemic stroke, myocardial infarction, and pulmonary embolism — but must be administered within a narrow time window to be effective and safe.

2.6 Clotting Regulation

Unchecked coagulation would be catastrophic. The body produces several natural anticoagulants that confine clotting to the injury site:

Anticoagulant	Mechanism
Antithrombin III	Inactivates thrombin (IIa) and factor Xa; activity greatly enhanced by heparin
Heparin	Naturally produced by basophils and mast cells; acts as a cofactor for antithrombin III
Protein C	Activated by thrombin-bound thrombomodulin on endothelial cells; degrades factors Va and VIIIa
Protein S	Cofactor for activated protein C
Tissue factor pathway inhibitor (TFPI)	Inhibits the VIIa–tissue factor complex and factor Xa
Prostacyclin (PGI₂)	Released by intact endothelial cells; inhibits platelet activation

Therapeutic anticoagulants:

Heparin (unfractionated and low-molecular-weight): activates antithrombin III; used acutely; monitored by aPTT
Warfarin: inhibits vitamin K recycling, reducing synthesis of factors II, VII, IX, X; oral; monitored by PT/INR
Direct oral anticoagulants (DOACs): dabigatran (direct thrombin inhibitor), rivaroxaban/apixaban (direct factor Xa inhibitors)

2.7 Clinical Disorders of Hemostasis

Hemophilia

Hemophilia A: deficiency of factor VIII (most common, ~80% of cases); X-linked recessive
Hemophilia B: deficiency of factor IX (Christmas disease); X-linked recessive
Both result in prolonged aPTT with normal PT and normal platelet count
Clinical: spontaneous bleeding into joints (hemarthrosis), deep muscle bleeds, prolonged bleeding after trauma/surgery
Treatment: recombinant factor VIII or IX concentrates

Thrombus and Embolus

Thrombus: a pathological clot that forms inside an intact vessel, obstructing blood flow
Embolus: a thrombus (or other material) that breaks free and travels through the circulation until it lodges in a smaller vessel
Consequences: deep vein thrombosis (DVT) → pulmonary embolism (PE); arterial thrombosis → myocardial infarction or stroke
Risk factors: Virchow's triad — endothelial injury, stasis (slow blood flow), hypercoagulability

Thrombocytopenia

Low platelet count (< 150,000/μL). Causes: bone marrow failure, autoimmune destruction (ITP), drug-induced. Presents with petechiae, easy bruising, mucosal bleeding.

2.8 ABO Blood Group System

The ABO blood group is determined by the presence or absence of A antigens and B antigens on the surface of red blood cells (RBCs). These are genetically determined carbohydrate chains attached to membrane glycoproteins and glycolipids.

ABO Blood Groups

Blood Type	Antigens on RBCs	Antibodies in Plasma	Can Donate RBCs To	Can Receive RBCs From
A	A antigen	Anti-B antibodies	A, AB	A, O
B	B antigen	Anti-A antibodies	B, AB	B, O
AB	Both A and B antigens	Neither anti-A nor anti-B	AB only	A, B, AB, O (universal recipient)
O	Neither A nor B	Both anti-A and anti-B	A, B, AB, O (universal donor)	O only

Key Principles

Antibodies in the ABO system are naturally occurring — they develop within the first few months of life in response to similar carbohydrate antigens on gut bacteria
These are predominantly IgM class antibodies that efficiently activate complement
Agglutination occurs when anti-A or anti-B antibodies bind to RBCs carrying the corresponding antigen, causing them to clump and hemolyze
Transfusion reaction: if type A blood is given to a type B recipient, the recipient's anti-A antibodies will attack the donor RBCs, causing massive hemolysis, kidney failure, shock, and potentially death

2.9 Rh Blood Group System

The Rh system centers on the D antigen (also called Rh factor), a transmembrane protein on RBCs.

Rh-positive (Rh+): 85% of Caucasians, ~95% of Africans/Asians — express D antigen on RBCs
Rh-negative (Rh−): do not express D antigen

Critical Difference from ABO

Unlike ABO antibodies, anti-Rh antibodies are NOT naturally occurring. They form only after an Rh− individual is exposed to Rh+ blood through:

Transfusion of Rh+ blood
Pregnancy with an Rh+ fetus (fetal-maternal hemorrhage during delivery)

Once formed, anti-Rh antibodies are IgG and can cross the placenta — this is the basis of hemolytic disease of the newborn.

2.10 Transfusion Compatibility

When transfusing RBCs, the primary concern is whether the recipient's antibodies will attack the donor's RBC antigens.

Compatibility Rules for Packed RBC Transfusion

Donor Type	Compatible Recipients
O−	All (A+, A−, B+, B−, AB+, AB−, O+, O−) — universal donor
O+	O+, A+, B+, AB+
A−	A+, A−, AB+, AB−
A+	A+, AB+
B−	B+, B−, AB+, AB−
B+	B+, AB+
AB−	AB+, AB−
AB+	AB+ only — universal recipient (can receive all types for RBCs)

Additional Testing

Before any transfusion, a cross-match is performed: donor RBCs are mixed with recipient plasma to directly check for agglutination.

2.11 Hemolytic Disease of the Newborn (Erythroblastosis Fetalis)

The Mechanism

This condition occurs when an Rh− mother carries an Rh+ fetus:

First pregnancy: During delivery, some fetal Rh+ RBCs enter the maternal circulation. The mother's immune system recognizes the D antigen as foreign and begins producing anti-Rh (anti-D) IgG antibodies. This is a primary immune response — it is slow, and the first baby is typically unaffected.

Second pregnancy with Rh+ fetus: The mother's pre-existing anti-Rh IgG antibodies can cross the placenta and attack fetal RBCs, causing hemolysis, severe anemia, heart failure, and widespread edema (hydrops fetalis). The fetal bone marrow releases immature RBCs (erythroblasts) into the circulation in a failed attempt to compensate — hence the name "erythroblastosis fetalis."

Prevention: RhoGAM

Rh immune globulin (RhoGAM) is a preparation of anti-Rh antibodies given as an injection:

Administered to Rh− mothers at ~28 weeks of gestation and within 72 hours of delivery
These passive antibodies destroy any fetal Rh+ cells in the maternal circulation before the mother's immune system mounts its own active response
By eliminating the antigen before sensitization occurs, RhoGAM prevents antibody formation and protects all future pregnancies
Also given after miscarriage, amniocentesis, abdominal trauma, or any event that may cause fetal-maternal bleeding

Eli explains

The same idea, in plain words

Explain it like I’m 10

ELI-10: Hemostasis — The Body's Emergency Repair Crew

Imagine you're riding your bike and scrape your knee. Blood starts coming out of a broken pipe (blood vessel). Your body sends out three emergency teams. Team 1 squeezes the pipe to slow the leak — like pinching a garden hose. Team 2 throws sticky patches (platelets) onto the hole, piling them up like a stack of sticky notes. Team 3 pours superglue (fibrin) over the sticky notes to make a hard, solid plug that won't wash away. Once the pipe underneath heals, a cleanup crew dissolves the glue so blood can flow again. The whole system is like having an instant repair kit inside your blood, ready to go the moment you get hurt.

ELI-10: Platelet Plug — Sticky Band-Aids

Platelets are tiny flat discs that float around in your blood minding their own business. When a blood vessel gets cut, collagen — a protein normally hidden under the vessel lining — gets exposed. It's like the concrete under a sidewalk cracking open. A special glue protein called von Willebrand factor sticks to the collagen, and platelets grab onto it like Velcro. Once stuck, the platelets get angry and change shape, throwing out spiky arms and shouting chemical signals to call more platelets over. They all link arms using fibrinogen bridges, forming a temporary band-aid made of living cells.

ELI-10: The Coagulation Cascade — Domino Chain

The coagulation cascade is like a row of dominoes. The first domino (factor XII in the intrinsic pathway, or tissue factor in the extrinsic pathway) gets tipped over by the injury. Each falling domino knocks the next one down — factor XII activates XI, which activates IX, which activates X. Factor X is the "super domino" that kicks off the final chain: X activates prothrombin into thrombin, and thrombin turns fibrinogen into fibrin. Fibrin is the stringy mesh that actually holds the clot together. The domino chain ensures that a tiny signal gets massively amplified into a big, robust response — one activated factor can turn on thousands of the next factor.

ELI-10: ABO Blood Types — Keys and Locks

Think of your red blood cells as houses, and the antigens (A and B) as doorknobs on those houses. Your immune system's antibodies are like security guards that only recognize doorknobs that don't belong. If you are type A, your red blood cells have A-shaped doorknobs, and your security guards attack B-shaped doorknobs. If you are type O, your cells have no doorknobs, so your guards attack both A and B. If someone gives you the wrong blood type, your security guards see foreign doorknobs and attack — the RBCs clump together like wet cereal and get destroyed, which can make you very sick.

ELI-10: Rh Incompatibility and RhoGAM — Vaccination in Reverse

A mother who is Rh-negative is like someone who has never seen the color red. If her first baby is Rh-positive (has red blood cells), some of those red cells might sneak into her bloodstream during delivery. Her immune system says "what's this?!" and makes antibodies against the red color. The first baby is fine because this takes too long. But if the next baby is also Rh-positive, those antibodies (which are small enough to cross the placenta) attack the baby's red blood cells. RhoGAM is like a cleanup crew injected into the mom — it destroys any fetal red cells that snuck in before her immune system has time to learn what red looks like. It's vaccination in reverse: instead of teaching the immune system to attack, it prevents the immune system from ever learning to attack.

Check yourself

12 review questions from the chapter. Try each one, then open the answer.

A blood vessel is injured. Which of the following represents the correct chronological sequence of hemostasis?
Show answer
Coagulation → platelet plug formation → vascular spasm → fibrinolysis B. Vascular spasm → platelet plug formation → coagulation → fibrinolysis C. Platelet plug formation → vascular spasm → fibrinolysis → coagulation D. Vascular spasm → coagulation → platelet plug formation → fibrinolysis Answer: B. Vascular spasm → platelet plug formation → coagulation → fibrinolysis Why It's the Answer: Hemostasis begins with immediate vasoconstriction (vascular spasm) to reduce blood flow, followed by platelet adhesion and aggregation forming the temporary plug. The coagulation cascade then generates fibrin to reinforce this plug. Only after the vessel heals does fibrinolysis dissolve the clot. Option A reverses the first two steps. Option C incorrectly places fibrinolysis before coagulation. Option D swaps coagulation and platelet plug formation — platelets must form the initial scaffold before fibrin reinforces it. ELI-10: It's like fixing a leaky pipe: first you squeeze the pipe (spasm), then you slap on sticky patches (platelet plug), then you apply glue over the patches (coagulation), and finally you peel everything off once the pipe is healed underneath (fibrinolysis).
A patient with von Willebrand disease has impaired platelet adhesion at sites of vascular injury. What is the normal role of von Willebrand factor in hemostasis?
Show answer
It converts fibrinogen into fibrin B. It activates factor X in the common pathway C. It bridges exposed collagen and platelet GPIb receptors D. It degrades fibrin during clot resolution Answer: C. It bridges exposed collagen and platelet GPIb receptors Why It's the Answer: vWF acts as a molecular bridge — one end binds exposed subendothelial collagen at the injury site, and the other end binds the GPIb receptor on platelets, tethering them to the vessel wall. Option A describes thrombin's action. Option B describes the role of factors IXa/VIIIa and VIIa/TF. Option D describes plasmin's action in fibrinolysis. ELI-10: vWF is like double-sided tape — one side sticks to the torn vessel wall (collagen) and the other side sticks to platelets, holding them in place so they can start building the plug.
Both the intrinsic and extrinsic coagulation pathways converge at the activation of which clotting factor?
Show answer
Factor V B. Factor VII C. Factor IX D. Factor X Answer: D. Factor X Why It's the Answer: The intrinsic pathway activates factor X via the IXa–VIIIa complex, and the extrinsic pathway activates factor X via the VIIa–tissue factor complex. Factor Xa then enters the common pathway to generate thrombin and fibrin. Factor V is a cofactor in the common pathway, not the convergence point. Factor VII is exclusive to the extrinsic pathway. Factor IX is exclusive to the intrinsic pathway. ELI-10: Think of factor X as the single entrance door to the final room where fibrin is made. There are two hallways (intrinsic and extrinsic) leading to that same door, but once you pass through factor X, there's only one path forward — the common pathway.
During fibrinolysis, the enzyme that directly digests fibrin strands into soluble degradation products is:
Show answer
Thrombin B. Tissue plasminogen activator (tPA) C. Plasmin D. Factor XIIIa Answer: C. Plasmin Why It's the Answer: Plasmin is the active enzyme that cleaves fibrin into soluble fibrin degradation products. Option A (thrombin) converts fibrinogen to fibrin — it builds the clot, it doesn't break it down. Option B (tPA) converts plasminogen to plasmin but does not directly digest fibrin. Option D (factor XIIIa) cross-links fibrin to stabilize the clot, the opposite of breaking it down. ELI-10: Plasmin is the scissors that cut up the fibrin net. tPA is the person who hands the scissors to plasminogen (turning it into plasmin). Thrombin is the person who wove the net in the first place, and factor XIIIa tied the knots — neither one does the cutting.
All of the following are natural anticoagulant mechanisms in the body EXCEPT:
Show answer
Antithrombin III inactivates thrombin and factor Xa B. Protein C degrades factors Va and VIIIa C. Tissue plasminogen activator (tPA) inhibits platelet aggregation D. Prostacyclin (PGI₂) released by endothelial cells reduces platelet activation Answer: C. Tissue plasminogen activator (tPA) inhibits platelet aggregation Why It's the Answer: tPA is a fibrinolytic agent — it activates plasminogen to dissolve clots. It does NOT inhibit platelet aggregation. Option A is correct: antithrombin III directly inactivates thrombin and factor Xa. Option B is correct: activated protein C cleaves and destroys factors Va and VIIIa, shutting down the common pathway. Option D is correct: prostacyclin from intact endothelial cells inhibits platelet activation to prevent inappropriate clotting on healthy vessel walls. ELI-10: tPA is on the cleanup crew (fibrinolysis), not the safety inspection team (natural anticoagulants). The body has separate teams: one that prevents clots from forming where they shouldn't (anticoagulants) and another that removes clots after they've done their job (tPA and plasmin). This question is asking about the prevention team — tPA doesn't belong there.
A 5-year-old boy presents with a painfully swollen right knee after a minor fall on the playground. He has a history of easy bruising and prolonged bleeding after dental procedures. Laboratory studies show a prolonged aPTT, normal PT, and normal platelet count. Which clotting factor is most likely deficient?
Show answer
Factor VII B. Factor VIII C. Factor X D. Fibrinogen (factor I) Answer: B. Factor VIII Why It's the Answer: Prolonged aPTT with normal PT localizes the defect to the intrinsic pathway. Factor VIII deficiency (Hemophilia A) is the most common inherited clotting factor deficiency, is X-linked recessive (explaining presentation in a male child), and classically presents with hemarthrosis (bleeding into joints) and prolonged bleeding after minor trauma. Option A (factor VII) deficiency would cause prolonged PT with normal aPTT — it is part of the extrinsic pathway. Option C (factor X) is in the common pathway; its deficiency would prolong both PT and aPTT. Option D (fibrinogen) deficiency would also prolong both PT and aPTT. ELI-10: Imagine the coagulation cascade as two toll roads (intrinsic and extrinsic pathways) leading to the same highway (common pathway). This boy's tests tell us the intrinsic toll road is broken but the extrinsic one works fine. Factor VIII is one of the toll booths on the intrinsic road. His swollen knee is like a leak that keeps dripping because the intrinsic repair crew can't finish the job.
A person with type A blood has which antibodies circulating in their plasma?
Show answer
Anti-A antibodies only B. Anti-B antibodies only C. Both anti-A and anti-B antibodies D. Neither anti-A nor anti-B antibodies Answer: B. Anti-B antibodies only Why It's the Answer: In the ABO system, plasma contains antibodies against the antigens NOT present on the individual's own RBCs. Type A individuals express A antigens, so they do not produce anti-A (would attack their own cells). They do produce anti-B antibodies because B antigen is foreign. Option A is incorrect — type B individuals have anti-A. Option C describes type O individuals. Option D describes type AB individuals. ELI-10: Your immune system's rule is: "Don't attack your own doorknobs, but attack any doorknob that looks different." If you're type A, your red blood cells have A doorknobs, so your security guards only carry weapons against B doorknobs. If you're type O (no doorknobs), you carry weapons against both — you're the most suspicious guard.
A trauma patient is brought to the emergency department with severe hemorrhage and requires an emergency RBC transfusion. The patient's blood type is unknown and there is no time for typing. Which blood type should be transfused?
Show answer
AB+ B. A− C. B+ D. O− Answer: D. O− Why It's the Answer: O− RBCs lack both A and B antigens and the Rh D antigen, meaning they will not be attacked by any recipient's ABO antibodies or anti-Rh antibodies. This makes O− the universal donor for packed RBC transfusions. Option A (AB+) has both A and B antigens plus the D antigen — it would be attacked by recipients with anti-A, anti-B, or anti-Rh antibodies. Options B and C each carry antigens that would trigger a reaction in incompatible recipients. ELI-10: O− blood is the "invisible" blood type — its red blood cells have no flags (antigens) on them, so no matter who receives it, the recipient's security guards see nothing to attack. It's like wearing camouflage that works against every security system.
A 28-year-old Rh-negative woman is pregnant with her second child. Her first child was Rh-positive and she did NOT receive RhoGAM after the first delivery. The current fetus is also Rh-positive. Which of the following best explains why the current fetus is at risk?
Show answer
The fetus has produced anti-Rh IgM antibodies that attack its own RBCs B. Maternal anti-Rh IgG antibodies formed after the first pregnancy can cross the placenta and destroy fetal RBCs C. The fetus inherited a defective clotting factor that causes spontaneous bleeding D. Maternal anti-A or anti-B antibodies are attacking the fetal Rh antigens Answer: B. Maternal anti-Rh IgG antibodies formed after the first pregnancy can cross the placenta and destroy fetal RBCs Why It's the Answer: During the first delivery, fetal Rh+ RBCs entered the maternal circulation, sensitizing the mother's immune system to produce anti-Rh IgG antibodies. In the second pregnancy, these pre-formed IgG antibodies cross the placenta and attack the Rh+ fetal RBCs, causing hemolysis. Without RhoGAM, this is the classic mechanism of erythroblastosis fetalis. Option A is incorrect — the fetus's immune system is immature and not the source of the problem. Option C confuses hemolytic disease with hemophilia, a completely different condition. Option D is incorrect because anti-A and anti-B are IgM antibodies (cannot cross the placenta) and do NOT target Rh antigens. ELI-10: Think of the first pregnancy as the mom's immune system attending a "wanted poster" briefing — it sees Rh-positive cells, memorizes the face, and builds tiny soldiers (IgG antibodies) that can slip through the placenta's gates. The first baby is born before the soldiers are trained. The second baby faces a full army already deployed. RhoGAM is like destroying all the wanted posters and witnesses from the first delivery so the mom's immune system never learns what to look for.
During platelet plug formation, which two substances released from activated platelets work together to recruit and activate additional platelets to the injury site?
Show answer
Fibrinogen and thrombin B. ADP and thromboxane A₂ C. Heparin and antithrombin III D. Tissue factor and factor VII Answer: B. ADP and thromboxane A₂ Why It's the Answer: Upon activation, platelets release ADP from dense granules and synthesize thromboxane A₂ from arachidonic acid. Both act as paracrine signals that recruit circulating platelets, make them sticky, and promote aggregation. Option A — fibrinogen bridges platelets but doesn't activate them, and thrombin is a coagulation factor, not a platelet granule product. Option C — heparin and antithrombin III are anticoagulants that inhibit clotting. Option D — tissue factor and factor VII initiate the extrinsic pathway, not platelet recruitment. ELI-10: ADP and thromboxane A₂ are like the distress flares and radio calls that activated platelets send out. When the first platelets arrive at the injury, they shout "WE NEED HELP!" using these two chemical messengers, and platelets floating nearby hear the call, rush over, and join the pile.
A patient on long-term warfarin therapy has an elevated PT and INR. Warfarin exerts its anticoagulant effect by interfering with the synthesis of which group of clotting factors?
Show answer
Factors V and VIII only B. von Willebrand factor and factor XIII C. Vitamin K-dependent factors II, VII, IX, and X D. Tissue factor (factor III) and factor XII Answer: C. Vitamin K-dependent factors II, VII, IX, and X Why It's the Answer: Warfarin inhibits the enzyme vitamin K epoxide reductase, preventing the recycling of vitamin K. This reduces hepatic synthesis of functional vitamin K-dependent clotting factors II (prothrombin), VII, IX, and X. The elevated PT reflects reduced factor VII (shortest half-life, extrinsic pathway). Option A — factors V and VIII are not vitamin K-dependent; they are inactivated by protein C. Option B — vWF is not vitamin K-dependent, and factor XIII is in the common pathway but not vitamin K-dependent. Option D — tissue factor is not a vitamin K-dependent factor, and factor XII is not affected by warfarin. ELI-10: Vitamin K is like a stamp of approval that the liver needs to put on factors II, VII, IX, and X before shipping them out. Warfarin jams the stamp machine. Without the stamp, those factors get made but are useless — they can't do their job in the coagulation cascade. The PT test shows this problem earliest because factor VII (which has the shortest shelf life in the blood) runs out first.
Which blood type can receive packed RBCs from donors of all ABO and Rh types without an ABO or Rh transfusion reaction?
Show answer
O+ B. AB+ C. A− D. B+ Answer: B. AB+ Why It's the Answer: AB+ individuals have A, B, and Rh D antigens on their RBCs but have NO anti-A, NO anti-B, and NO pre-formed anti-Rh antibodies in their plasma. Since transfusion reactions are caused by recipient antibodies attacking donor RBC antigens, AB+ recipients have no antibodies to attack any donor's RBCs. Option A (O+) has both anti-A and anti-B antibodies — it cannot receive A, B, or AB blood. Option C (A−) has anti-B antibodies and could form anti-Rh antibodies if exposed to Rh+ blood. Option D (B+) has anti-A antibodies. ELI-10: AB+ is the most welcoming blood type — it's like the host who says "everyone is welcome at my party." Because AB+ blood has all the possible doorknobs (antigens) on its own cells, its security guards are trained to attack nothing. Everyone else has at least one type of security guard ready to attack some visitor.